GlassScriptPhysician profile
Adam B Rosenbluth
NPI 1083766729
$1,148,746.59
in general payments reported to CMS, 2019-2025
54 companies · $130K in 2025
The $130K reported for 2025 was more than what 99% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $254K · 2020: $153K · 2021: $128K · 2022: $208K · 2023: $152K · 2024: $124K · 2025: $130K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $347K · Travel and Lodging: $42K · Food and Beverage: $18K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $346,513.06 |
| Travel and Lodging | $41,777.44 |
| Food and Beverage | $17,787.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $343,185.22 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $301,676.70 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $272,082.98 | 2019-2025 | Jardiance |
| Boston Scientific Corporation | $91,089.06 | 2019-2025 | Watchman Access System, Watchman Flx, Lux-Dx Insertable Cardiac Monitor |
| Lilly USA, LLC | $86,602.11 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Sanofi-Aventis U.S. LLC | $42,371.67 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,512.72 | 2019-2025 | Xifaxan, Trulance |
| Novartis Pharmaceuticals Corporation | $1,414.23 | 2019-2025 | |
| Amgen INC. | $909.29 | 2019-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $855.03 | 2019-2024 | Xarelto |
| Intra-Sana Laboratories | $745.79 | 2023-2025 | Reltone 400 Mg, Glycate, Reltone 200 Mg |
| Glaxosmithkline, LLC. | $742.06 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $716.56 | 2019-2024 | |
| Xeris Pharmaceuticals, INC. | $529.80 | 2024-2025 | Gvoke Hypopen, Recorlev |
| Abbvie INC. | $468.62 | 2022-2025 | Vraylar, Synthroid, Linzess |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Rosenbluth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.